How to cash in on investment trusts that are selling up
Managed wind-downs and portfolio sales can be an attractive opportunity for patient investors
Last year saw record consolidation and corporate action in the investment trust sector. If the past seven months are anything to go by, 2025 will be a year of note as well. At the beginning of the year, 20 trusts were undergoing managed wind-downs, and since January, a further six have proposed or had wind-downs approved, according to Deutsche Numis.
Wind-downs usually happen because an asset class, strategy or individual trust is out of favour. At the same time, they can present a new opportunity if they offer a timetable and a catalyst for realising value from a portfolio that is persistently trading at a deep discount to net asset value (NAV).
This is especially true in the alternative-asset segment of the market. That said, alternatives trusts normally own illiquid assets, which means it can take some time to realise value. If a buyer cannot be found for the entire portfolio, the trust must sell assets piecemeal. Take NB Distressed Debt (LSE: NBDG) as an example: it began to wind down in 2018 and is still ongoing – although the board hopes it has entered the final stages of asset sales, according to its latest update. So this kind of investing certainly is not a trade for anybody with a short-term time horizon.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Investment trusts winding down
Abrdn European Logistics Income (LSE: ASLI) entered a managed wind-down last year following a failed sales process for the entire portfolio. It sold three assets in the first quarter of the year and returned an initial £16.5 million to investors (5.3% of its NAV). Following additional sales, 16 of its 27 assets have now been liquidated and further capital returns are planned in August and September. The estimated NAV is now 57.9p, reckon analysts at Deutsche Numis, putting the shares on a discount of 17%.
JPMorgan Global Core Real Assets (LSE: JARA) failed a continuation vote in September and is now returning assets to investors. The first cash from sales, totalling £33 million or 17% of NAV, was paid in February. Further sales are in the pipeline, and the trust expects to redeem 80% of assets by the end of 2026. The end-June NAV of 89.1p implies the shares are trading at a discount of 11%.
Following a strategic review, Riverstone Energy (LSE: RSE) has proposed a managed wind-down, with investors set to vote on this on 22 August. Management has laid out a plan to distribute two-thirds of the capital by 31 March 2026, with the remaining illiquid assets sold by the end of 2027. The trust’s reported discount has recently narrowed to 22%, based on the latest NAV of 1,136p.
Investors need to be aware that the manager is getting a termination fee of 7.5% of realisation proceeds, but even allowing for that, the discount is still in double-digits.
Investment trusts to watch
Syncona (LSE: SYNC), the once high-flying backer of early-stage biotech companies, announced in June that it will wind down its portfolio. The trust has said it will aim to continue supporting key companies in its portfolio and open a private vehicle for those investors interested in rolling their investment over. This puts a question mark over the liquidation timetable, but with a discount of about 40% there could be a lot of value there for patient investors.
Life Science Reit (LSE: LABS), which announced a strategic review in March, recently said it has received significant interest from buyers for parts of the portfolio. Management is also continuing to explore a managed wind-down. The portfolio includes assets at Oxford Technology Park and Cambourne Park Science & Tech Campus – both located in two high-growth, tech-focused areas of the country – and King’s Cross in London. The Reit has struggled since listing (recent leasing has been slower than expected, with occupancy now at 85%) and has suspended its dividend. But at a 32% discount to NAV, it is worth watching closely.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Rupert is the former deputy digital editor of MoneyWeek. He's an active investor and has always been fascinated by the world of business and investing. His style has been heavily influenced by US investors Warren Buffett and Philip Carret. He is always looking for high-quality growth opportunities trading at a reasonable price, preferring cash generative businesses with strong balance sheets over blue-sky growth stocks.
Rupert has written for many UK and international publications including the Motley Fool, Gurufocus and ValueWalk, aimed at a range of readers; from the first timers to experienced high-net-worth individuals. Rupert has also founded and managed several businesses, including the New York-based hedge fund newsletter, Hidden Value Stocks. He has written over 20 ebooks and appeared as an expert commentator on the BBC World Service.
-
The UK areas which saw biggest jump in asking prices in 2025 – is yours on the list?We look at the UK areas where asking prices rose the most last year.
-
‘Sandwich generation’ carers losing £6,000 a year to support elderly relativesMiddle-aged adults are often caught between caring for children or grandchildren and their elderly parents, leaving them taking time out of the workforce and facing a huge hit to wages while they are still trying to save for retirement. We look at the true cost of caring.
-
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
-
How to add cryptocurrency to your portfolioA new listing shows how bitcoin might add value to a portfolio if cryptocurrency keeps gaining acceptance, says Cris Sholto Heaton
-
Three funds to buy for capital growth and global incomeOpinion Three investment trusts with potential for capital growth, selected by Adam Norris, co-portfolio manager of the CT Global Managed Portfolio Trust
-
Investing in forestry: a tax-efficient way to grow your wealthRecord sums are pouring into forestry funds. It makes sense to join the rush, says David Prosser
-
The MoneyWeek investment trust portfolio – early 2026 updateThe MoneyWeek investment trust portfolio had a solid year in 2025. Scottish Mortgage and Law Debenture were the star performers, with very different strategies
-
Pundits had a bad 2025 – here's what it means for investorsThe pundits came in for many shocks in 2025, says Max King. Here is what they should learn from them
-
Polar Capital: a cheap, leveraged play on technologyPolar Capital has carved out a niche in fund management and is reaping the benefits
-
'Investors should keep putting their trust in investment trusts'Interview Peter Walls, manager of the Unicorn Mastertrust fund, analyses investment trusts in a conversation with Andrew Van Sickle